STOCK TITAN

Lilly Eli & Co Stock Price, News & Analysis

LLY NYSE

Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.

Lilly Eli & Co (LLY) delivers innovative healthcare solutions through cutting-edge pharmaceutical research and global therapeutic development. This news hub provides investors and industry professionals with timely updates on corporate milestones, regulatory developments, and scientific advancements.

Access official press releases, earnings reports, and analysis of key initiatives across diabetes, oncology, and immunology research. Our curated collection ensures you stay informed about FDA decisions, partnership announcements, and manufacturing expansions without promotional bias.

Discover updates on clinical trial progress, sustainability efforts, and market leadership in biotechnology. Bookmark this page for streamlined access to verified information that supports informed decision-making in the evolving pharmaceutical landscape.

Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced on October 27, 2025 that the U.S. FDA approved a single‑injection, once‑monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab‑mrkz) for adults with moderately to severely active ulcerative colitis.

The approval follows an EU authorization and is supported by a Phase 1 bioequivalence study comparing one 200 mg/2 mL injection to two 100 mg/1 mL injections. The single‑injection, citrate‑free maintenance dose will be available in the U.S. via prefilled pen or syringe in early 2026. Omvoh retains existing safety warnings for allergic reactions, infections, and liver problems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) declared a fourth-quarter 2025 dividend of $1.50 per share on outstanding common stock.

The dividend is payable on December 10, 2025 to shareholders of record at the close of business on November 14, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced on Oct 27, 2025 a nationwide partnership with Shaquille O'Neal to expand the "Don't Sleep on OSA" campaign and raise awareness of moderate-to-severe obstructive sleep apnea (OSA).

The initiative highlights that an estimated 24 million U.S. adults may have OSA, outlines common symptoms (loud snoring, choking/gasping, daytime sleepiness), and directs people to DontSleepOnOSA.com to learn more and talk to their healthcare provider.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Eli Lilly (NYSE: LLY) reported Phase 3b LUCENT-URGE results showing early, sustained improvement in bowel urgency for adults with moderately to severely active ulcerative colitis treated with Omvoh (mirikizumab‑mrkz).

Key outcomes: 55% reduction in daily bowel urgency episodes by Week 12 (maintained at Week 28), 52% reduction in urgency severity by Week 28, and increase in patients able to delay a bowel movement ≥15 minutes from 4.1% at baseline to 29.7% at Week 28. Safety was consistent with prior LUCENT data: 5.2% serious adverse events and 4.7% discontinuations due to adverse events. Results will be presented at ACG Oct 24–29, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary

Eli Lilly (NYSE:LLY) agreed to acquire Adverum Biotechnologies for $3.56 cash per share plus one CVR, with the CVR payable up to $8.91 for total potential consideration of $12.47 per share. The deal funds a tender offer and a second-step merger, is expected to close in Q4 2025, and requires a majority tender. Lilly provided a secured $65 million promissory note to support Adverum operations pre-close. Adverum's lead asset, Ixo-vec, is a Phase 3 intravitreal gene therapy for wet AMD (ARTEMIS trial completed screening) with Fast Track, RMAT, EMA PRIME, and UK Innovation Passport designations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
-
Rhea-AI Summary

Lilly (NYSE: LLY) reported 52-week Phase 3 BRAVE-AA-PEDS results showing once-daily oral baricitinib 4 mg produced substantial hair regrowth in adolescents (ages 12 to <18) with severe alopecia areata.

Key one-year outcomes: 54.1% achieved ≥80% scalp hair coverage (SALT ≤20) on 4 mg versus 31% on 2 mg; 41.2% on 4 mg achieved ≥90% scalp coverage (SALT ≤10). In the severe-disease subgroup (SALT 50–94), 71% on 4 mg achieved successful regrowth. Eyebrow and eyelash regrowth rates were also higher on 4 mg. Safety was consistent with prior trials; no deaths, opportunistic infections, MACEs, or VTEs were reported.

Lilly plans to submit these adolescent data to global regulators for a potential label update for Olumiant and to enroll younger children in BRAVE-AA-PEDS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
Rhea-AI Summary

Eli Lilly (NYSE: LLY) reported Phase 3 ADjoin extension data on Oct. 24, 2025 showing EBGLYSS (lebrikizumab-lbkz) maintained high disease control when switched from monthly maintenance dosing to a single 250 mg injection every eight weeks (Q8W).

Key results: EASI-75 rates were 79% Q8W vs 86% Q4W; IGA 0,1 rates were 62% Q8W vs 73% Q4W. No new safety signals or increased immunogenicity were observed. Lilly submitted these data to the FDA seeking a potential label update to offer an every-eight-week maintenance option; an every-twelve-week study is underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

Lilly (NYSE: LLY) announced primary overall survival results from the Phase 3 monarchE trial showing two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus endocrine therapy alone (7-year OS: 86.8% vs 85.0%; HR 0.842; 95% CI 0.722–0.981; 2-sided p=0.027) with median follow-up of 6.3 years. The regimen also showed sustained benefits in invasive disease-free survival and distant relapse-free survival, and 32% fewer patients were living with metastatic disease (6.4% vs 9.4%). Safety was consistent with prior analyses; data were published in Annals of Oncology and presented at ESMO on Oct 17, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
-
Rhea-AI Summary

Eli Lilly (NYSE: LLY) will release its third-quarter 2025 financial results on October 30, 2025.

The company will host a conference call for investors and media on the same day beginning at 10:00 a.m. Eastern time, with a live webcast and a replay available via the investor website at https://investor.lilly.com/webcasts-and-presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences earnings
Rhea-AI Summary

Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for oral GLP-1 orforglipron from ACHIEVE-2 and ACHIEVE-5 on Oct 15, 2025. At week 40, orforglipron doses (3 mg, 12 mg, 36 mg) met primary and all key secondary endpoints for both efficacy and treatment-regimen estimands, delivering meaningful A1C reductions and weight loss versus comparators.

Key numeric results: ACHIEVE-2 A1C change vs dapagliflozin (efficacy estimand) was -1.3%/ -1.7%/ -1.7% (3/12/36 mg) vs -0.8%; ACHIEVE-5 with insulin glargine showed -1.5%/ -2.1%/ -1.9% vs -0.8% for placebo. Safety was consistent with prior studies; common adverse events were GI-related and generally mild-to-moderate.

Lilly expects ACHIEVE-4 readout in Q1 2026 and plans regulatory submissions for type 2 diabetes in 2026; obesity submission remains on track for year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags

FAQ

What is the current stock price of Lilly Eli & Co (LLY)?

The current stock price of Lilly Eli & Co (LLY) is $826.41 as of October 27, 2025.

What is the market cap of Lilly Eli & Co (LLY)?

The market cap of Lilly Eli & Co (LLY) is approximately 740.0B.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

739.98B
944.35M
0.16%
83.87%
0.9%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS